Josselin Nespoux1, Volker Vallon. 1. British Heart Foundation Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, UK Department of Medicine, University of California, San Diego & VA San Diego Healthcare System Department of Pharmacology, University of California San Diego, San Diego, USA.
Abstract
PURPOSE OF REVIEW: SGLT2 inhibitors are a new class of antihyperglycemic drugs that protect kidneys and hearts of type 2 diabetic (T2DM) patients with preserved kidney function from failing. Here we discuss new insights on renal protection. RECENT FINDINGS: Also in T2DM patients with CKD, SGLT2 inhibition causes an immediate functional reduction in glomerular filtration rate (GFR) and reduces blood pressure and preserves kidney and heart function in the long-term, despite a lesser antihyperglycemic effect. According to modeling studies, the GFR reduction reduces the tubular transport work and metabolic demand, thereby improving renal cortical oxygenation. In humans, the latter is linked to protection from CKD. Urine metabolomics in T2DM patients suggested improved renal mitochondrial function in response to SGLT2 inhibition, and experimental studies indicated improved tubular autophagy. Modeling studies predicted that also in diabetic CKD, SGLT2 inhibition is natriuretic and potentially stimulates erythropoiesis by mimicking systemic hypoxia in the kidney. Meta-analyses indicated that SGLT2 inhibition also reduces risk and severity of acute kidney injury in T2DM patients. Studies in nondiabetic mice implied inhibition of the renal urate transporter URAT1 in the uricosuric effect of SGLT2 inhibition. SUMMARY: Renoprotection of SGLT2 inhibition involves blood glucose-dependent and independent effects and extends to CKD.
PURPOSE OF REVIEW: SGLT2 inhibitors are a new class of antihyperglycemic drugs that protect kidneys and hearts of type 2 diabetic (T2DM) patients with preserved kidney function from failing. Here we discuss new insights on renal protection. RECENT FINDINGS: Also in T2DM patients with CKD, SGLT2 inhibition causes an immediate functional reduction in glomerular filtration rate (GFR) and reduces blood pressure and preserves kidney and heart function in the long-term, despite a lesser antihyperglycemic effect. According to modeling studies, the GFR reduction reduces the tubular transport work and metabolic demand, thereby improving renal cortical oxygenation. In humans, the latter is linked to protection from CKD. Urine metabolomics in T2DM patients suggested improved renal mitochondrial function in response to SGLT2 inhibition, and experimental studies indicated improved tubular autophagy. Modeling studies predicted that also in diabetic CKD, SGLT2 inhibition is natriuretic and potentially stimulates erythropoiesis by mimicking systemic hypoxia in the kidney. Meta-analyses indicated that SGLT2 inhibition also reduces risk and severity of acute kidney injury in T2DM patients. Studies in nondiabetic mice implied inhibition of the renal urate transporter URAT1 in the uricosuric effect of SGLT2 inhibition. SUMMARY: Renoprotection of SGLT2 inhibition involves blood glucose-dependent and independent effects and extends to CKD.
Authors: Tatiana Yakovleva; Victor Sokolov; Lulu Chu; Weifeng Tang; Peter J Greasley; Helena Peilot Sjögren; Susanne Johansson; Kirill Peskov; Gabriel Helmlinger; David W Boulton; Robert C Penland Journal: Diabetes Obes Metab Date: 2019-09-09 Impact factor: 6.577
Authors: Aaron Y Kluger; Kristen M Tecson; Clay M Barbin; Andy Y Lee; Edgar V Lerma; Zachary P Rosol; Janani Rangaswami; Norman E Lepor; Michael E Cobble; Peter A McCullough Journal: Rev Cardiovasc Med Date: 2018-06-30 Impact factor: 2.930
Authors: Sergei Petrykiv; C David Sjöström; Peter J Greasley; John Xu; Frederik Persson; Hiddo J L Heerspink Journal: Clin J Am Soc Nephrol Date: 2017-03-16 Impact factor: 8.237
Authors: William G Herrington; David Preiss; Richard Haynes; Maximilian von Eynatten; Natalie Staplin; Sibylle J Hauske; Jyothis T George; Jennifer B Green; Martin J Landray; Colin Baigent; Christoph Wanner Journal: Clin Kidney J Date: 2018-10-25
Authors: Jan M Williams; Sydney R Murphy; Wenjie Wu; Jane J Border; Fan Fan; Richard J Roman Journal: Geroscience Date: 2022-06-29 Impact factor: 7.581
Authors: Thomas Wilke; Nils Picker; Sabrina Müller; Anna Stürmlinger; Barthold Deiters; Axel Dittmar; Jens Aberle; Maximilian Gabler Journal: Clinicoecon Outcomes Res Date: 2022-05-02
Authors: Takahiko Nakagawa; Laura G Sanchez-Lozada; Ana Andres-Hernando; Hideto Kojima; Masato Kasahara; Bernardo Rodriguez-Iturbe; Petter Bjornstad; Miguel A Lanaspa; Richard J Johnson Journal: Front Immunol Date: 2021-06-16 Impact factor: 7.561